title: Residents' corner September 2011. Residents' editorial choice.
authors.affiliation: University Hospital Zurich, Gloriastrasse 31, Zurich, Switzerland. lfeldmeyer@gmail.com
authors.forename: Laurence
authors.initials: L
authors.lastname: Feldmeyer
authors.forename: Emmanuella
authors.initials: E
authors.lastname: Guenova
authors.forename: Tiago
authors.initials: T
authors.lastname: Torres
authors.forename: Audrey
authors.initials: A
authors.lastname: Nosbaum
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000453:epidemiology*; D003606:Dacarbazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy*; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D000074324:Ipilimumab; C540586:LFA3-IgG1 fusion protein, human; D011993:Recombinant Fusion Proteins; D003606:Dacarbazine